Apomorphine or ropinirole? New data sharpen the emetic choice

A once-simple choice in canine decontamination is getting more nuanced. Apomorphine has long been the go-to emetic in dogs, particularly in emergency settings, but ropinirole ophthalmic solution has introduced a labeled, in-clinic alternative that’s now backed by several years of post-approval experience and a growing body of comparative research. The practical question for veterinary professionals is no longer whether ropinirole works, but where it fits best relative to apomorphine. (fda.gov)

Ropinirole entered the U.S. market with a regulatory advantage. The FDA approved Clevor in June 2020 as a prescription ophthalmic solution for inducing vomiting in dogs, and the agency said it should be administered only by veterinary personnel because professional assessment is needed to confirm that emesis is appropriate and to monitor for adverse reactions. In the pivotal field study cited by FDA, 95% of dogs vomited within 30 minutes, with 86% responding after the first dose. Reported drug-related effects included tremors, lethargy, tachycardia, and decreased blood pressure, which resolved within six hours after dosing. (fda.gov)

That approval addressed a longstanding gap: apomorphine has been widely used in dogs, but it does not have FDA approval in the U.S. for emesis induction. The University of Illinois College of Veterinary Medicine notes that apomorphine is used extra-label, can be administered by multiple routes, and is often much faster when given IV, with time to emesis of roughly 1 to 5 minutes compared with about 12 minutes for ropinirole. Illinois also highlights operational differences that matter in practice: ropinirole is a labeled ophthalmic product, while apomorphine typically must be compounded from bulk drug powder, and apomorphine handling raises hazardous-drug concerns for staff. (vetmed.illinois.edu)

The head-to-head evidence is where the discussion gets more interesting. A 2023 study in client-owned dogs with known or suspected toxin or foreign-material ingestion found ropinirole was less effective than apomorphine at inducing vomiting overall, 91.4% versus 95.6%, but similarly effective at evacuating all ingested material, 74.2% versus 75.6%. That suggests the two drugs may perform more similarly on the clinically meaningful endpoint of gastric clearance than on the narrower endpoint of whether vomiting occurs at all. (pubmed.ncbi.nlm.nih.gov)

But a newer 2025 emergency-department study leaned more clearly in apomorphine’s favor. As summarized by VetGirl, Reeves and colleagues conducted a prospective randomized clinical trial from October 2021 through March 2023 at 2 specialty referral hospitals, enrolling 132 client-owned dogs after suspected or confirmed ingestion of a toxin or foreign body. Dogs were randomized to topical ropinirole in 63 dogs or IV apomorphine in 69 dogs. If vomiting did not occur within 20 minutes, the same dose was repeated, and dogs were monitored for 40 minutes for emetic success, time to first emetic event, number of emetic episodes, and the need for antiemetic rescue. Cases included toxic foods such as chocolate, xylitol, grapes, and raisins; plants; medications; rodenticides and other poisons; and foreign material including toys, cords, and cloth items. (pubmed.ncbi.nlm.nih.gov)

Investigators reported that ropinirole had a lower first-dose emetic success rate, a longer median time to the first emetic event, more minor adverse events, and a higher frequency of protracted vomiting requiring rescue therapy. The authors concluded that IV apomorphine appeared clinically superior for dogs presenting to the emergency department for rapid decontamination. That’s an important distinction, because the best drug in a controlled setting may not be the best drug when minutes matter and the patient has ingested a high-risk toxin or foreign body. The same trial also reinforces how selective appropriate use remains: excluded dogs included those younger than 4.5 months, weighing less than 1.8 kg, with apparent ocular disease, with a history of CNS or hepatic disease, with contraindicated ingestions such as caustic or volatile substances, or with prior antiemetic treatment before presentation. (pubmed.ncbi.nlm.nih.gov)

Industry and educational commentary reflects that same split. Illinois frames ropinirole as a comparatively safer option for staff and for appropriately selected patients, especially when a labeled product is preferred and there are no ophthalmic contraindications. At the same time, the same source notes that apomorphine may carry more serious adverse effects, including CNS and respiratory depression, even as many clinicians continue to favor it for speed and familiarity. In other words, the tradeoff is not simply efficacy versus safety, but speed, route, labeling status, staff handling, patient selection, and the urgency of decontamination. (vetmed.illinois.edu)

Why it matters: For veterinary professionals, this is a protocol question with real implications for triage, staffing, and client communication. In ER and urgent care, IV apomorphine may remain the preferred option when rapid decontamination is critical. In general practice, or in cases where a labeled product, easier administration, or reduced staff exposure is a priority, ropinirole may be an attractive alternative for dogs that meet the label criteria. Either way, clinicians still need to decide first whether emesis is appropriate at all. Illinois emphasizes that emesis should generally be avoided in dogs that have ingested hydrocarbons, corrosives, or sharp objects, in dogs that have already vomited, or in patients with conditions that increase aspiration or airway risk. (vetmed.illinois.edu)

What to watch: The next development to watch is whether newer comparative studies change hospital protocols, CE messaging, or toxicology recommendations around first-line emetic choice by case type. If additional emergency-setting data continue to favor apomorphine for speed and first-dose success, ropinirole may settle into a more selective role rather than replacing apomorphine outright. Separately, clinics may also be tracking adjacent supportive-care updates: Dechra has announced FDA approval of Emeprev, an injectable maropitant bioequivalent for dogs and cats that requires no refrigeration and, in healthy laboratory dogs, caused less discomfort after subcutaneous injection than the pioneer drug, with availability expected through major veterinary distributors in early 2026.